Mitra Biotech Inc,  a biotech company that develops and provides technologies that personalize cancer treatment, has raised approximately INR 184 crore in a Series B round of financing led by Sequoia India and Sands Capital Ventures.Mitra Biotech is engaged in supporting personalized oncology therapy selection and drug development. Founded in 2010, Mitra is based in Boston, and maintains a significant research and laboratory presence in Bengaluru. The funding will be utilized to expand the availability of its CANScript service, which predicts personalized responses to cancer treatments.